Health Catalyst insider files Form 144 for 2,854-share sale on NASDAQ
Rhea-AI Filing Summary
Health Catalyst, Inc. (HCAT) Form 144 notice reports a proposed sale of 2,854 common shares with an aggregate market value of $9,597.15, to be sold through Morgan Stanley Smith Barney LLC on 09/02/2025 on NASDAQ. The shares were acquired on 09/02/2025 as restricted stock from Health Catalyst, Inc. and were granted as compensation. The filer represents they are not aware of undisclosed material adverse information. The filing also discloses a prior sale by Linda Llewelyn of 2,965 restricted shares on 06/02/2025 for gross proceeds of $10,777.18.
Positive
- Filer provided required Rule 144 details: class, quantity, broker, exchange, acquisition date, and nature of acquisition (compensation).
- Planned sale routed through a registered broker (Morgan Stanley Smith Barney LLC) and lists NASDAQ as the market.
Negative
- Insider sold restricted shares recently: 2,965 shares sold on 06/02/2025 for gross proceeds of $10,777.18, which is disclosed in the filing.
Insights
TL;DR Form 144 notifies a planned Rule 144 sale of 2,854 restricted shares acquired as compensation; filing appears procedural and compliant.
The filing documents a proposed sale under Rule 144 through a registered broker, names the broker and exchange, and states acquisition and payment details explicitly: restricted stock acquired and paid as compensation on the same date listed. It includes a recent related sale by the same person in June 2025. From a compliance perspective, the submission contains the core elements required for a Rule 144 notice: class, quantity, acquisition details, sale timing, broker, and a representation about undisclosed material information.
TL;DR Transaction size is modest and routine; filing signals a planned insider disposition via broker on NASDAQ.
The notice shows a small, single-party disposition (2,854 shares, ~$9.6k) to be executed on a specified date via Morgan Stanley Smith Barney. The shares were acquired as restricted compensation on the same date listed and are being sold under Rule 144. A prior sale of 2,965 restricted shares generated ~$10.8k in June 2025. The amounts disclosed are small in absolute terms relative to typical public-company float, suggesting limited market impact; all material transaction details are provided in the form.